Scribe Therapeutics Inc. Common Stock (SCTX) - Total Assets
Based on the latest financial reports, Scribe Therapeutics Inc. Common Stock (SCTX) holds total assets worth $57.93 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does Scribe Therapeutics Inc. Common Stock generate cash for how efficiently the company converts equity into cash flow.
Scribe Therapeutics Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Scribe Therapeutics Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See SCTX stock price for real-time trading data and today's change.
Scribe Therapeutics Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Scribe Therapeutics Inc. Common Stock's total assets of $57.93 Million consist of 85.6% current assets and 14.4% non-current assets. Explore working capital to net assets of Scribe Therapeutics Inc. Common Stock to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Scribe Therapeutics Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scribe Therapeutics Inc. Common Stock's current assets represent 85.6% of total assets in 2025, a decrease from 86.3% in 2024.
- Cash Position: Cash and equivalents constituted 16.4% of total assets in 2025, up from 9.9% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Scribe Therapeutics Inc. Common Stock Competitors by Total Assets
Key competitors of Scribe Therapeutics Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.71 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
Scribe Therapeutics Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.57 | 0.66 | - |
| Quick Ratio | 0.57 | 0.66 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $-33.59 Million | $-27.32 Million | - |
Scribe Therapeutics Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Scribe Therapeutics Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 5.00 |
| Asset Growth Rate (YoY) | -38.9% |
| Total Assets | $78.22 Million |
| Market Capitalization | $391.32 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Scribe Therapeutics Inc. Common Stock's assets at a significant premium (5.00x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Scribe Therapeutics Inc. Common Stock's assets decreased by 38.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scribe Therapeutics Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Scribe Therapeutics Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $78.22 Million | -38.88% |
| 2024-12-31 | $127.97 Million | -- |
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more